# Wei Wang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/wei-wang-4/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,132 |
| Field | Lung Cancer Diagnosis and Treatment |
| h-index | 57 |
| i10-index | 261 |
| Last Known Institution | Central South University |
| OpenAlex ID | https://openalex.org/A5100392329 |
| ORCID iD | 0009-0003-7539-9394 |
| Works | 778 |

## Researcher papers

- [Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China](https://scholariq.org/papers/cancer-patients-in-sars-cov-2-infection-a-nationwide-analysis-in-china/)
- [Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis](https://scholariq.org/papers/comorbidity-and-its-impact-on-1590-patients-with-covid-19-in-china-a-nationwide/)
- [Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China](https://scholariq.org/papers/dysregulation-of-immune-response-in-patients-with-covid-19-in-wuhan-china/)
- [Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis](https://scholariq.org/papers/comorbidity-and-its-impact-on-1-590-patients-with-covid-19-in-china-a-nationwide/)
- [Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial](https://scholariq.org/papers/ruxolitinib-in-treatment-of-severe-coronavirus-disease-2019-covid-19-a/)
- [Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China](https://scholariq.org/papers/clinical-characteristics-and-outcomes-of-hospitalised-patients-with-covid-19/)
- [Early triage of critically ill COVID-19 patients using deep learning](https://scholariq.org/papers/early-triage-of-critically-ill-covid-19-patients-using-deep-learning/)
- [Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study](https://scholariq.org/papers/circulating-mir-15b-and-mir-130b-in-serum-as-potential-markers-for-detecting/)
- [Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial](https://scholariq.org/papers/neoadjuvant-cemiplimab-for-resectable-hepatocellular-carcinoma-a-single-arm-open/)
- [Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma](https://scholariq.org/papers/fatty-acid-oxidation-controls-cd8-tissue-resident-memory-t-cell-survival-in/)
- [Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial](https://scholariq.org/papers/modified-xeliri-capecitabine-plus-irinotecan-versus-folfiri-leucovorin/)
- [Low-carbon retrofit of rural dwellings in the dabie mountain region of China based on life-cycle assessment](https://scholariq.org/papers/low-carbon-retrofit-of-rural-dwellings-in-the-dabie-mountain-region-of-china/)

## Researcher topics

- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Respiratory Support and Mechanisms](https://scholariq.org/topics/respiratory-support-and-mechanisms/)
- [Tracheal and airway disorders](https://scholariq.org/topics/tracheal-and-airway-disorders/)

## Researcher university

- [Central South University](https://scholariq.org/institutions/central-south-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.